/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
SAN DIEGO, CA, Aug. 21 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX: NVN) announces that further to its press release dated August 10, 2007,
the company now expects to close its short form prospectus offering of units
on Wednesday, August 22, 2007.
The securities offered under this short form prospectus have not been and
will not be registered under the United States Securities Act of 1933, as
amended, or any state securities laws and may not be offered or sold in the
United States or to persons in the United States unless registered or an
exemption from such registration is available.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please
visit the company's website located at www.nventacorp.com.
For further information:
For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Tel: (858) 202-4900,
Fax: (858) 450-6849, email@example.com